In the neoadjuvant setting, HR-positive/HER2-positive BC patients have a reduced chance of achieving a pathological complete response after neoadjuvant chemotherapy and anti-HER2 agents as compared to the HR-negative/HER2-positive subgroup7,8. Here, ERBB2 is linked to breast cancer.